@article {DE FELICE4673, author = {FRANCESCA DE FELICE and DANIELA MUSIO and NICOLA RAFFETTO and VINCENZO TOMBOLINI}, title = {Neoadjuvant Strategy as Initial Treatment in Resectable Pancreatic Cancer: Concrete Evidence of Benefit}, volume = {34}, number = {9}, pages = {4673--4676}, year = {2014}, publisher = {International Institute of Anticancer Research}, abstract = {Pancreatoduodenectomy remains the recommended treatment in potentially curative strategies for pancreatic carcinoma. Due to high local failure rates even after complete resection, a multi-modality treatment approach is paramount in the management of resectable disease. Despite there being insufficient evidence to recommend a specific neoadjuvant strategy, several studies have tested the use of preoperative chemoradiotherapy in this sub-group of patients, achieving promising results. The treatment is well-tolerated, with higher rates of negative margins and lower rates of lymph node positivity at resection, a decrease in local failure and benefit in overall survival. Considering the poor oncological results after primary surgical treatment, neoadjuvant strategy should be considered as a valid alternative in resectable pancreatic carcinoma.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/34/9/4673}, eprint = {https://ar.iiarjournals.org/content/34/9/4673.full.pdf}, journal = {Anticancer Research} }